INS and type 1 diabetes mellitus: Another promising area of hPSC-based cell therapy development is the treatment of type 1 diabetes (T1D; see Glossary, Box 1), a chronic autoimmune disease in which pancreatic β-cells that secrete insulin and regulate blood glucose are destroyed (DiMeglio et al., 2018).